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A b s t r a c t
Introduction: Sipuleucel-T is a novel active cellular immunotherapy for the treat-
ment of asymptomatic or minimally symptomatic metastatic castrate-resistant
prostate cancer (mCRPC). It is assumed to be associated with less adverse events
than conventional docetaxel-based chemotherapy.
Material and methods: A systematic review of literature published between Jan-
uary, 1 1966 and February, 6 2012 was performed to assess the efficacy and safe-
ty of sipuleucel-T in patients with mCRPC. Databases were searched: Medline,
EMBASE, Cochrane, CancerLit as well as ASCO and ESCO websites. 
Results: Three randomized clinical trials with a total of 737 participants fulfilled
established criteria. The overall survival of patients who received sipuleucel-T
in comparison to the control group was significantly longer with a hazard ratio
(HR) of 0.73 (95% CI: 0.61-0.88; p = 0.001). Time to disease progression was not
prolonged using sipuleucel-T compared to placebo, HR = 0.89 (95% CI: 0.75-1.05;
p = 0.18). Relative benefit (RB) of serum PSA level reduction of at least 50% for
sipuleucel-T compared to placebo did not meet statistical significance, RB = 1.97
(95% CI: 0.48-8.14; p = 0.38). The safety population consisted of 729 patients
with mCRPC. Compared to the control group, the pooled relative risks (RR) of all
adverse events – RR = 1.03 (95% CI: 1.00-1.05; p = 0.06), grade 3 to 5 adverse
events – RR = 0.98 (95% CI: 0.79-1.22; p = 0.86) and cerebrovascular events –
RR = 1.93 (95% CI: 0.73-5.09; p = 0.18) were not significantly higher for men
treated with sipuleucel-T.
Conclusions: The use of sipuleucel-T prolonged the overall survival among men
with mCRPC. No effect on time to disease progression was observed and
the safety profile was acceptable.
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Introduction
Prostate cancer is one of the most common malignant forms of can-
cer among men [1]. Between 2005 and 2009 there were about 7,900 new
cases of the disease among Polish patients and the standardized incidence
ratio for 2009 was 32.8. There were also around 3900 deaths due to
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prostate cancer each year and the standardized
mortality rate for 2009 was 13.1 [2]. Low level
of oncological awareness (i.e. screening tests used
for the early detection of prostate cancer) results
in late diagnosis and poor outcome [3].
Localized prostate cancer may be cured with sur-
gery or radiation therapy, but the disease recurs in
approximately 19% to 32% of patients [4-8]. Andro-
gen-deprivation therapy, the most common treat-
ment after recurrence, is effective; however, the
disease eventually progresses in most men who
receive such treatment [9]. Management of this cas-
tration-resistant state, also known as androgen-
independent prostate cancer (AIPC), is a significant
clinical challenge. It remains an incurable disease,
given the availability of treatment options that mod-
estly extend survival by a median of 2 to 4 months.
Docetaxel-based regimens have been acknowl-
edged as the standard first-line chemotherapy [10],
but are associated with serious adverse effects 
(i.e., grade 3 or 4 neutropenia, infection, anemia, neu-
ropathy) [11]. New treatments with fewer side
effects are needed [12, 13].
Sipuleucel-T is an active cellular immunothera-
py, a type of therapeutic cancer vaccine, consisting
of autologous peripheral-blood mononuclear cells
(PBMCs), including antigen-presenting cells (APCs)
that have been activated ex vivo with a recombi-
nant fusion protein (PA2024). This protein consists
of a prostate antigen, prostatic acid phosphate, that
is fused to a granulocyte-macrophage colony-stim-
ulating factor: an immune-cell activator [13]. On
April 29, 2010, the Food and Drug Administration
(FDA) approved the drug sipuleucel-T (PROVENGE®,
made by the Dendreon Corporation) for the treat-
ment of asymptomatic or minimally symptomatic
metastatic castrate-resistant (hormone refractory)
prostate cancer [14].
The aim of this review was to identify all
of the randomized controlled trials comparing sip-
uleucel-T to placebo for men with mCRPC and to
provide reliable evidence on the efficacy and safe-
ty of the novel therapy.
Material and methods
Data sources and searches
The study was conducted according to the pre-
ferred reporting items for systematic reviews and
meta-analyses (PRISMA) guidelines [15]. A system-
atic search of electronic databases, abstract pro-
ceedings of major scientific meetings, and bibli-
ographies of all eligible studies published between
January 1, 1966 and February 6, 2012 was conduct-
ed to identify all of the relevant studies. Databas-
es searched included Medline (PubMed), Embase,
Cochrane Registry of Controlled Trials (CENTRAL)
and, additionally, the ISI Web of Science, Scopus,
CancerLit, American Society of Clinical Oncology
(ASCO), and European Society of Medical Oncolo-
gy (ESMO). 
The search strategy involved the following terms
combined with Boole's logical operators [16]: ("sip-
uleucel" OR "sipuleucel T" OR "sipuleucel-T" OR 
"APC-8015" OR "APC8015" OR "APC 8015" OR
"Provenge" OR "PA024 Antigen") for intervention
AND ("prostate cancer*" OR "prostatic neoplasm*"
OR "prostate neoplasm*" OR "cancer of the prostate"
OR "cancer of prostate" OR "prostatic cancer*" OR
"prostate gland cancer") for population. The search
results were restricted to humans and methodolog-
ical filters were used to identify clinical trials and ran-
domized clinical trials. Studies were considered irre-
spective of language or publication status.
Study selection
Randomized controlled trials investigating
the effectiveness of sipuleucel-T for men with
metastatic castration-resistant prostate cancer were
eligible for inclusion. Although all of the relevant
records were identified and included in the sys-
tematic review, the meta-analysis was based on
full-text articles only.
Data extraction and quality assessment
A coherent form was created, piloted, and then
used to abstract the available data for the prede-
fined outcomes of interest. These were: overall sur-
vival (OS), time to progression (TTP), probability
of at least 50% reduction of the PSA level, adverse
events of any grade, and adverse events grades 3
to 5. Two authors extracted data independently.
Disagreements were resolved by discussion, con-
sensus, and arbitration by a third author. 
The Jadad score, which evaluates studies based
on their description of randomization, blinding, 
and dropouts (withdrawals), was used to assess
the methodological quality of the trials [17].
The quality scale ranges from 0 to 5 points with
a low-quality report for a score of 2 or less and
a high-quality report for a score of at least 3.
Data synthesis and analysis
Relative benefit (RB) or relative risk (RR) and 95%
confidence intervals (95% CI) were used to sum-
marize the probability of at least a 50% reduction
of the PSA level and adverse events. Hazard ratios
(HR) and 95% CI were used for overall survival (OS)
and time to progression (TTP). The median "time-
to-event" data and range were also presented for
OS and TTP. 
Relative benefits were calculated as the propor-
tion of occurrence frequency for the particular out-
come between the two treatment arms and their
95% confidence intervals were calculated using the
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χ2 test. The hazard ratios with the confidence inter-
vals were acquired from original papers according to
their authors. As the approach to calculating these
statistics may have varied across the studies, an
effort was made to extract the parameter from all
of the studies calculated with the unadjusted Cox
regression model. Due to the inconsistency in pre-
senting hazard ratio values (the HR defined as
the risk in patients treated with a placebo divided by
the risk for patients treated with sipuleucel-T), it was
necessary to calculate the inverse value in such
instances.
The results obtained from separate trials were
combined using appropriate meta-analysis meth-
ods. The inverse variance, Mantel-Haenszel or Der
Simonian-Laird effects model, was used according
to the data input and heterogeneity test results. 
The clinical heterogeneity was assessed by
examining characteristics of the featured studies,
whereas the statistical heterogeneity was detect-
ed using formal testing with Cochrane Q and
the inconsistency level I2 [16]. The possibility
of publication bias was not assessed due to
the very limited number of studies included [18].
Meta-analysis was performed with RevMan® V 5.1.
(The Nordic Cochrane Centre Software, Copen-
hagen) [19], and the relevant calculations were
made using Microsoft Office Excel 2007® (Micro -
soft® Corporation) [20].
Due to the limited data available, the meta-
analysis was not carried out in subgroups and only
the results for the general population were pre-
sented.
Results
Systematic review
The electronic searches yielded 548 items after
duplicates were removed. Of these, 24 articles were
fully scrutinized. Twelve of the studies were con-
sidered ineligible due to lack of randomization, use
of combination therapy with another anti-cancer
agent, review or systematic review, different popu-
lation or irrelevant outcomes. Twelve articles and
conference abstracts met the predefined inclusion
criteria [21-32]. The flow of information through
the different phases of the systematic review is
shown in Figure 1.
The studies included in the meta-analysis com-
prised full texts of 3 randomized clinical trials
(RCTs): D9901 trial [21], the D9902A trial published
together with data from the D9901 trial [25], and
the IMPACT (Immunotherapy for Prostate Adeno-
carcinoma Treatment) study [26]. A total of 737 par-
ticipants were randomized, with 488 patients hav-
ing taken sipuleucel-T and 249 patients having
taken a placebo. All of the studies were homoge-
neous with regard to the patients' age, diagnosis,
basic biochemical parameters, and methodological
aspects, e.g. Jadad score (Table I). 
Quantitative assessment – efficacy
The assessed efficacy of sipuleucel-T versus
the placebo comprises results for the following clin-
ically important outcomes: HR for overall survival,
HR for time to disease progression, median survival
Figure 1. PRISMA flow diagram for the database search for sipuleucel-T vs. placebo for treatment of castration-resis-
tant prostate cancer (CRPC)
Records screened after duplicates
removed (n = 548)
Full-text articles assessed for 
eligibility (n = 24)
Studies included in quantitative 
synthesis (meta-analysis) (n = 3)
Articles or conference proceedings
included in qualitative synthesis 
(n = 12)
Records excluded on basis of title 
(n = 522)
Full-text articles excluded, with reasons:
n = 1 – combination therapy with bevacumab
n = 4 – lack of randomization
n = 5 – reviews and systematic reviews
n = 1 – not relevant outcomes
n = 1 – different population (men with androgen
dependent prostate cancer)
Records identified through main
database searching (n = 43)
Additional records identified through
other sources (n = 627)
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time, median time to disease progression, and at
least a 50% reduction of the serum PSA level.
Overall survival
Three trials that included 737 randomized partic-
ipants contributed the information on overall sur-
vival [21, 25, 26]. The median survival time was pre-
sented for each study separately for sipuleucel-T and
the placebo group, and a meta-analysis of hazard
ratios was performed. The median time of overall
survival was 4.5 months longer in sipuleucel-T 
than in the placebo group for patients in D9901 [21],
3.3 months longer in the D9902A trial [25], and 
4.1 months longer in the IMPACT trial [26] (Table II).
Because event rates for time intervals were not avail-
able in the studies, we used the inverse variance
Parameter D9901 D9902A IMPACT 
(Small et al. 2006) [21] (Higano et al. 2009) [25] (Kantoff et al. 2010) [26]
Number Sipuleucel-T 82 65 341
of participants Placebo 45 33 171
in study group 
Median age Approx. 72 years (47-86) Approx. 71 years (51-87) Approx. 70 years (40-91)
of participants
Diagnosis and Men with asymptomatic Men with asymptomatic Men with metastatic 
eligibility criteria metastatic hormone refractory metastatic hormone refractory castration-resistant
prostate cancer (HRPC); prostate cancer (HRPC); prostate cancer; 
expected survival expected survival expected survival 
of at least 3 months of at least 3 months of at least 6 months; 
any Gleason score; 
patients with 
asymptomatic 
disease or minimally 
symptomatic
Median serum Approx. 47 ng/ml Approx. 50 ng/ml > 5 ng/ml; 
prostate specific (3.5-3621.0 ng/ml) (8.0-1342.0 ng/ml) approx. 50.0 ng/ml
antigen (PSA) 
level (range)
Serum < 50 ng/dl (< 17 nmol/l) < 50 ng/dl (< 17 nmol/l) < 50 ng/dl (< 17 nmol/l)
testosterone 
level
Design Double-blind, randomized; Double-blind, randomized; Double-blind, randomized; 
possibility to allocate possibility to allocate possibility to allocate 
from placebo group from placebo group from placebo group 
after disease progression after disease progression after disease progression
Randomization 2 : 1; block randomization 2 : 1; block randomization 2 : 1; stratified by: 
stratified by: study center stratified by: study center Gleason score, number 
and bisphosphonate use and bisphosphonate use of bone metastases, 
bisphosphonate use
Jadad score 3 3 3
Table I. Characteristics and methodological quality of the randomized controlled trials for sipuleucel-T compared to
placebo for castration-resistant prostate cancer
Parameter Group D9901 D9902A IMPACT 
(Small et al. 2006) [21] (Higano et al. 2009) [25] (Kantoff et al. 2010) [26]
Median overall Sipuleucel-T 25.9 (20.0-32.4) 19.0 (13.6-31.9) 25.8 
survival [months] Placebo 21.4 (12.3-25.8) 15.7 (12.8-25.4) 21.7
Median time to Sipuleucel-T 11.7 (9.1-16.6) 10.9 (9.3-17.7) 14.6
progression [weeks] Placebo 9.1 (8.7-13.1) 9.9 (8.4-18.0) 14.4
Table II. Median time of overall survival and time to progression from individual trials for sipuleucel-T compared to
placebo for castration-resistant prostate cancer
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method to pool summary log hazard ratios from 
individual trials, confirming the strong positive influ-
ence of sipuleucel-T on the overall survival of men 
with castration-resistant prostate cancer (Figure 2, 
Table III). The survival effect with sipuleucel-T was
observed despite the inclusion of optional APC8015F
salvage therapy for placebo-treated patients.
Time to progression 
Three trials that included 737 randomized par-
ticipants contributed the information on time to
progression (TTP) [21, 25, 26]. The median time to
progression was presented for each study sepa-
rately for the sipuleucel-T and placebo groups and
a meta-analysis of hazard ratios was performed.
The median TTP was 2.6 weeks longer in the sip-
uleucel-T group than in the placebo group for
patients in D9901 [21], 1 week longer in the D9902A
trial [25], and 0.2 weeks longer in the IMPACT trial
[26] (Table II). Both the median time to disease pro-
gression and a meta-analysis of hazard ratios for
this outcome indicate that a significant effect of sip-
uleucel-T on disease progression was not observed
(Figure 3, Table III).
Serum PSA level reduction of at least 50%
Data on reduction of the serum PSA level of at
least 50% were available from one randomized con-
trol trial [26]. The analysis included 464 randomized
participants for whom the post-baseline serum PSA
level was assessed. Relative benefit (RB) was cal-
culated but a statistical difference between treat-
ment arms was not observed (Table III). 
Quantitative assessment – safety
All adverse events and adverse events 
grades 3 to 5
The incidence of adverse events was available
from three randomized control trials [21, 25, 26].
The analysis was based on a safety population
(patients who underwent at least 1 leukaphere-
sis) of 729 men with castration-resistant prostate
cancer randomized to sipuleucel-T or placebo.
The analyzed population consisted of an inte-
grated safety population from D9901 and D9902A
trials [25] consisting of 223 of 225 men, and a safe-
ty population from the IMPACT trial [26] that
included 506 of 512 patients. The analysis includ-
ed the overall incidence of adverse events, and
the occurrence of adverse events with grades 3 to
5 (according to the National Cancer Institute's
Common Toxicity Criteria version 2.0 [25] or 3.0
[26]). The pooled relative risk (RR) of occurrence
of adverse events (Figure 4) and adverse events
grades 3 to 5 (Figure 5) indicated lack of statisti-
cal difference between the therapy with sipuleu-
cel-T and the placebo regarding those safety end-
points (Table III). 
Figure 2. Forest plot representing the effects of therapy with sipuleucel-T and placebo use on hazard ratio of over-
all survival in men with CRPC
Study or log Sipuleucel-T Placebo Rate ratio IV, 
subgroup [rate ratio] SE Total Total Weight fixed, 95% CI
D9901 [21] –0.54 0.211 82 45 20.3% 0.58 [0.39, 0.88]
D9902A [25] –0.24 0.249 65 33 14.6% 0.79 [0.48, 1.28]
IMPACT [26] –0.26 0.118 341 171 65.0% 0.77 [0.61, 0.97]
Total (95% CI) 488 249 100.0% 0.73 [0.61, 0.88]
Heterogeneity: χ2 = 1.44, df = 2 (p = 0.49); I2 = 0%
Test for overall effect: Z = 3.30 (p = 0.0010) 0.5 0.7 1 1.5 2
Sipuleucel-T Placebo
Rate ratio IV, 
fixed, 95% CI
Parameter References Results Value of p
Overall survival Meta-analysis (D9901 [21], HR = 0.73 (95% CI: 0.61-0.88) 0.001
Time to progression D9902A [25], IMPACT [26]) HR = 0.89 (95% CI: 0.75-1.05) 0.17
Serum PSA level reduction of at least 50% IMPACT [26] RB = 1.97 (95% CI: 0.48-8.14) 0.38
All adverse events Meta-analysis (D9901 [21], RR = 1.03 (95% CI: 1.00-1.05) 0.06
Adverse events grades 3 to 5 D9902A [25], IMPACT [26]) RR = 0.98 (95% CI: 0.79-1.22) 0.86
Cerebrovascular events Meta-analysis (D9901 and RR = 1.93 (95% CI: 0.73-5.09) 0.18
D9902A [25], IMPACT [26])
Table III. Efficacy and safety meta-analysis and single study results for sipuleucel-T compared to placebo for castra-
tion-resistant prostate cancer
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Cerebrovascular events
The most serious adverse events possibly relat-
ed to sipuleucel-T use were cerebrovascular events
(e.g., hemorrhagic, ischemic, embolic, transient
ischemic attack, and bleeding from a dural
metastatic lesion). Data on the probability of cere-
brovascular events were available from three ran-
domized control trials: integrated data from
the D9901 and D9902A trials [25] and the IMPACT
trial [26]. The safety population included 729 ran-
domized participants who underwent at least one
leukapheresis. The meta-analysis results (Figure 6,
Table III) did not confirm the influence of sipuleu-
cel-T on the increased risk of cerebrovascular
events.
Discussion
All of the studies included in the meta-analysis
are of good quality and are homogeneous with
regard to their clinical aspects. Nevertheless, two
of them (D9901 [21] and D9902A [25]) were
designed to evaluate the time to disease progres-
sion (TTP) rather than overall survival as a primary
endpoint. 
The results of the meta-analysis in the present
review confirm the findings reported by authors [21,
Figure 4. Forest plot representing effects of sipuleucel-T and placebo use on probability of incidence of all adverse
events (any grade) in men with CRPC
Study or Sipuleucel-T Placebo Risk ratio M-H, 
subgroup Events Total Events Total Weight fixed, 95% CI
D9901 and 145 147 73 76 30.8% 1.03 [0.98, 1.08]
D9902A [25]
IMPACT [26] 334 338 162 168 69.2% 1.02 [0.99, 1.06]
Total (95% CI) 485 244 100.0% 1.03 [1.00, 1.05]
Total events 479 235
Heterogeneity: χ2 = 0.01, df = 1 (p = 0.94); I2 = 0%
Test for overall effect: Z = 1.86 (p = 0.06)
0.5 0.7 1 1.5 2
Sipuleucel-T Placebo
Risk ratio M-H, 
fixed, 95% CI
Figure 5. Forest plot representing effects of sipuleucel-T and placebo use on incidence of grade 3 to 5 adverse events
in men with CRPC
Study or Sipuleucel-T Placebo Risk ratio M-H, 
subgroup Events Total Events Total Weight fixed, 95% CI
D9901 and 49 147 21 76 26.0% 1.21 [0.78, 1.85]
D9902A [25]
IMPACT [26] 107 338 59 168 74.0% 0.90 [0.70, 1.17]
Total (95% CI) 485 244 100.0% 0.98 [0.79, 1.22]
Total events 156 80
Heterogeneity: χ2 = 1.30, df = 1 (p = 0.25); I2 = 23%
Test for overall effect: Z = 0.17 (p = 0.86)
0.5 0.7 1 1.5 2
Sipuleucel-T Placebo
Risk ratio M-H, 
fixed, 95% CI
Figure 3. Forest plot representing effects of therapy with sipuleucel-T and placebo use on hazard ratio of time to
progression in men with CRPC
Study or log Sipuleucel-T Placebo Rate ratio IV, 
subgroup [rate ratio] SE Total Total Weight fixed, 95% CI
D9901 [21] –0.37 0.193 82 45 20.2% 0.69 [0.47, 1.01]
D9902A [25] –0.09 0.23 65 33 14.2% 0.91 [0.58, 1.43]
IMPACT [26] –0.05 0.107 341 171 65.6% 0.95 [0.77, 1.17]
Total (95% CI) 488 249 100.0% 0.89 [0.75, 1.05]
Heterogeneity: χ2 = 2.12, df = 2 (p = 0.35); I2 = 6%
Test for overall effect: Z = 1.39 (p = 0.17) 0.5 0.7 1 1.5 2
Sipuleucel-T Placebo
Rate ratio IV, 
fixed, 95% CI
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25, 26] that treatment with the therapeutic cancer
vaccine sipuleucel-T led to a significant improve-
ment in overall survival for men with metastatic
castration-resistant prostate cancer. 
By contrast, the time to disease progression did
not differ significantly between treatment arms.
This result may be due to the delayed onset of
antitumor responses after active immunotherapy,
relative to objective disease progression, which
occurred early in this group of patients [33]. In
patients with metastatic castration-resistant
prostate cancer, the disease progression endpoint,
as currently defined, is not a reliable predictor
of overall survival. Several randomized trials that
have shown effects of various treatments on over-
all survival have not shown the effects on disease
progression [34-37], and vice-versa [38], suggesting
a possible class effect or some previously unknown
feature of prostate cancer. 
The preliminary results of the PROTECT (PROvenge
Treatment and Early Cancer Treatment) trial, in -
cluding men with androgen-dependent prostate
cancer, have also failed to achieve statistical sig-
nificance for their primary endpoint, which is bio-
chemical failure (defined as serum PSA level 
≥ 3.0 ng/ml); however, the survival results are not
yet available [39].
Moreover, with the median time to progression
of 10-14 weeks, many patients had progressed 
by the time of the first scan scheduled at 6 or 
8 weeks, so that patients may have reached
the progression endpoint before achieving
the maximal immune response to therapy. As was
previously demonstrated, the maximal immune
response in some patients may not occur until 
12 weeks or longer after the initiation of therapy
[40]. Progression may therefore have reflected, in
part, what was in progress at the time of enroll-
ment, and not necessarily progression on
the therapy. For this reason, the time to progres-
sion may not be an appropriate endpoint when
testing the effect of immunotherapy in this
patient population. 
Overall survival may be a more appropriate end-
point for advanced prostate cancer trials, because
death events generally occur much later than pro-
gression events, allowing more time for the thera-
py to take effect, particularly for immunotherapeutic
agents such as sipuleucel-T. 
The mechanisms by which sipuleucel-T provides
a clinical benefit are not yet completely understood.
However, knowledge of these mechanisms will be
crucial for probing human immune responses and
tumor biology in order to understand what distin-
guishes responders from non-responders. The fol-
lowing next steps are necessary: firstly, the devel-
opment of immune-monitoring strategies for
the identification of relevant biomarkers; secondly,
the establishment of guidelines for the assessment
of clinical endpoints; and thirdly, the evaluation
of combination therapy strategies to improve clin-
ical benefit [41, 42].
In conclusion, sipuleucel-T is safe and prolongs
survival among men with asymptomatic or mini-
mally symptomatic metastatic castration-resistant
prostate cancer. However, no significant effect on
the time to objective disease progression was
observed. 
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